• יו״ר: ד"ר צבי פישל
  • יו"ר יוצא: פרופ' חיים בלמקר
  • יו"ר נבחר: פרופ' יובל מלמד
  • מזכירה: ד"ר מרינה קופצ'יק
  • גזברית: ד"ר לירון בודינגר
  • עורך IJP: פרופ' ישראל שטראוס
  • עורך האתר: ד"ר גלעד אגר
וידאו

Highlights from Prof Fagiolini lecture - Israel, May 2019

הרצאתו של פרופ' פג'יוליני, על טיפול בדיכאון, תל אביב, 5 במאי, 2019

Treatment of depression, which has traditionally only focused on depressive symptoms in general, should target all three domains (emotional, cognitive and physical) to increase the chances of functional recovery.

Clinical Practice indicates that:

1. There is not a medication that is always better than the others for each and any patient
2. Antidepressants are profoundly different in terms of ability to work for specific patients and specific symptoms
3. Antidepressants are different in terms of tolerability and side effects profile
4. Vortioxetine is an effective, safe, effective and well tolerated medication, able to work well on mood, cognition, executive functions, interests, motivation, energy, and neurovegetative functions

Comparative efficacy and acceptability of 21 antidepressants of the acute treatment of MDD (Cipriani, The Lancet 2018)

Vortioxetine/ Brintellix MOA

Getting well but not getting better: Vortioxetine and Cognition

Functionality improvement: why is so important? The role of Vortioxetine

New Data on emotional blunting

Depression is a complex disease with many unmet needs

להרצאה המלאה:

נושאים קשורים:  וידאו